The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab

Competing interests

R.S.H. has received consulting fees from AbbVie, AstraZeneca, Bolt Biotherapeutics, Bristol Myers Squibb, Candel Therapeutics, Checkpoint Therapeutics, Cybrexa Therapeutics,…